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After injury to the vessel wall, platelets adhere 
to the subendothelial matrix and aggregate 
with one another to form a primary hemostatic 
plug (1, 2). Phosphatidyl serine (PS) exposure 
on the surface of activated platelets provides a 
thrombogenic surface for the activation of the 
coagulation protease cascade (3, 4). PS-exposed 
membranes enhance the catalytic effi   ciency of 
membrane-anchored tissue factor (TF) (5), the 
primary initiator of the coagulation cascade 
that leads to the conversion of prothrombin to 
thrombin and fi  brinogen to fi  brin (6). Whether 
circulating platelets intrinsically possess TF 
protein, however, is a debated question (7–12). 
Studies have demonstrated that monocyte-
  derived microparticles bind to activated platelets 
(13–15) and activated platelets themselves re-
lease TF-positive microparticles (9, 16, 17).
We report here that platelets from healthy 
human subjects contain TF pre-mRNA and 
process it to the mature transcript in response 
to cellular activation. Activated platelets also 
TF protein, procoagulant activity, and acceler-
ate plasma clot formation. The intracellular 
  signaling pathway that controls TF pre-mRNA 
splicing involves Cdc2-like kinase (Clk)1, an 
enzyme not previously known to be pres-
ent or operate in platelets. Inhibition of Clk1 
sig  naling in activated platelets blocks splic-
ing factor 2 (SF2)/alternative splicing factor 
(ASF) phosphorylation, TF pre-mRNA splic-
ing, and de novo accumulation of bioactive 
TF protein. Collectively, these data indicate 
that Clk1-dependent splicing of TF pre-mRNA 
in platelets is a previously unrecognized path-
way to fi  brin formation and stabilization of a 
platelet thrombus.
RESULTS AND DISCUSSION
Activated platelets splice TF pre-mRNA
To address the question of whether or not platelets 
express TF, we fi   rst determined if platelets 
contained TF mRNA using highly purifi  ed 
platelet preparations that were isolated from 
healthy volunteers (reference 18; Supplemental 
Materials and methods, available at http://www.
jem.org/cgi/content/full/jem.20061302/DC1). 
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Tissue factor (TF) is an essential cofactor for the activation of blood coagulation in vivo. 
We now report that quiescent human platelets express TF pre-mRNA and, in response to 
activation, splice this intronic-rich message into mature mRNA. Splicing of TF pre-mRNA 
is associated with increased TF protein expression, procoagulant activity, and accelerated 
formation of clots. Pre-mRNA splicing is controlled by Cdc2-like kinase (Clk)1, and inter-
ruption of Clk1 signaling prevents TF from accumulating in activated platelets. Elevated 
intravascular TF has been reported in a variety of prothrombotic diseases, but there is 
debate as to whether anucleate platelets—the key cellular effector of thrombosis—express 
TF. Our studies demonstrate that human platelets use Clk1-dependent splicing pathways to 
generate TF protein in response to cellular activation. We propose that platelet-derived TF 
contributes to the propagation and stabilization of a thrombus.
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The leukocyte-depleted preparations did not express CD45, 
PSGL-1, or CD14 (Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20061302/DC1, and unpublished 
data). Unexpectedly, we found that stimulated, but not 
quiescent, human platelets contain TF mRNA (Fig. 1 A); 
this was confi  rmed by amplifi  cation of the entire TF mes-
sage and subsequent cloning of the PCR product (Fig. S2, 
available at http://www.jem.org/cgi/content/full/jem.
20061302/DC1, and unpublished data). We did not de-
tect the alternatively spliced variant of TF (19) in stimulated 
platelets under the conditions of these experiments; the 
  variant was detected, however, in HL60 myeloid leuko-
cytes or resting primary human monocytes (Fig. 1 A and 
  unpublished data).
We surmised that unstimulated platelets contain intronic-
rich TF transcripts, a feature that can prevent translation of 
the corresponding protein until an appropriate signal induces 
splicing and assembly of the mature mRNA (18). We de-
signed primer sets that fl  ank intron four and found that freshly 
isolated platelets predominantly contain TF pre-mRNA (Fig. 
1, B and C, see Fig. 4 A, and Fig. S3 A, http://www.jem.
org/cgi/content/full/jem.20061302/DC1), a fi  nding that was 
consistent in >40 subjects (unpublished data).
We next determined if platelets activated by fi  brinogen 
and thrombin splice TF pre-mRNA into a mature transcript. 
Splicing of TF pre-mRNA was detected at 5 min, neared 
completion by 1 h, and was sustained for at least 4 h after the 
platelets were activated (Fig. 1, B and C). Other agonists such 
as ADP, collagen, or thrombin also induce TF pre-mRNA 
splicing in suspended platelets (Fig. S3). We have recently 
demonstrated that anucleate platelets possess a functional 
  spliceosome and can splice pre-mRNAs when activated (18), 
Figure 1.  Platelets contain TF pre-mRNA and splice it into ma-
ture message in response to activation. (A) TF and GAPDH mRNA 
expression in freshly isolated platelets (0 min), platelets adherent to 
fi  brinogen and coactivated with thrombin (Fib + Thr), or HL60 leuko-
cytes. The negative control lane (Neg con) is a PCR reaction conducted 
without cDNA template. A is representative of two independent experi-
ments. (B and C) TF and GAPDH mRNA expression in freshly isolated 
platelets (Control) or platelets that are adherent to fi  brinogen in the 
presence of thrombin (Fib + Thr). The negative control lane (Neg con) 
in C is a PCR reaction conducted without cDNA template. B and C are 
representative of >10 independent experiments. (D) Indirect in situ PCR 
for intronic TF pre-mRNA in megakaryocytes (left) and megakaryocytes 
with proplatelet extensions (right). In the bottom panels (no RT), the 
reverse transcriptase (RT) was omitted from the RT reaction. (E) Direct 
in situ PCR for TF pre-mRNA was conducted in quiescent platelets 
(top left), whereas PCR for mature TF mRNA was conducted in platelets 
  adherent to fi  brinogen in the presence of thrombin for 1 h (top right). 
In the bottom panels (no RT), the reverse transcriptase was omitted 
during the RT reaction. D and E are representative of three indepen-
dent experiments.JEM VOL. 203, October 30, 2006  2435
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establishing a mechanism for this sequence of events (20). 
Cloning and sequencing of the unspliced and spliced PCR 
products confi  rmed that they were TF (unpublished data). 
To unequivocally demonstrate the cell source of pre- and 
mature TF mRNA species, we screened for the transcripts in 
individual megakaryocytes, proplatelets, and mature platelets. 
Figure 2.  Platelet activation increases TF-dependent procoagu-
lant activity. (A and B) A timecourse (A, 0–60 min; B, 0–4 h) of TF-
  dependent procoagulant activity in platelets that have adhered to 
fi  brinogen in the presence of thrombin. In B, each line represents proco-
agulant activity from platelet membranes (Plts), platelet-derived micro-
particles (Mp), or platelet membranes together with microparticles from 
the same sample (Plts + Mp). The data are displayed as pM of TF per 
2 × 109 platelets and represent the mean ± SEM of three independent 
experiments. (C) Immunolocalization of TF in freshly isolated platelets 
(left) and platelets that have adhered and spread on immobilized fi  brino-
gen in the presence of thrombin for 2 h (right). The green stain in both 
panels represents actin. The red stain in the right panel shows immuno-
localization of TF on the surface of activated platelets (see arrow). This 
experiment is representative of two independent studies. (D and E) The 
bars (n = 4) in these panels show TF-dependent procoagulant activity in 
freshly isolated platelets or platelets activated as in B for 4 h in the pres-
ence or absence of factor VIIa (D) or a neutralizing antibody directed 
against TF (E). A single asterisk (*) indicates a statistically signifi  cant 
difference (P < 0.05) in TF-dependent procoagulant activity between 
freshly isolated (baseline) and activated platelets; the double asterisk (**) 
represents a signifi  cant difference (P < 0.05) between activated platelets 
under untreated or treated conditions. (F) These panels show clot forma-
tion in plasma that is incubated with membranes isolated from quies-
cent platelets or platelets activated with fi  brinogen and thrombin for 
5 min (left) or 2 h (right). The white bars represent activated platelets 
that were incubated with a neutralizing antibody directed against tis-
sue factor (Anti-TF). The data represent the mean ± SEM of six inde-
pendent experiments.2436  TISSUE FACTOR PRE-MRNA SPLICING IN PLATELETS | Schwertz et al.
TF pre-mRNA was present in the cytoplasm of hematopoi-
etic stem cell–derived human megakaryocytes and proplate-
lets (Fig. 1 D). Consistent with detection of intronic-rich 
message in platelet precursors, we found TF pre-mRNA in 
freshly isolated platelets from circulating human blood (Fig. 
1 E, top left). We also found that activated platelets express TF 
mRNA (Fig. 1 E, top right), confi  rming that the mature 
message is derived from platelets.
Stimulated platelets generate bioactive TF
Since stimulated platelets use their splicing machinery to pro-
duce mature TF mRNA, we asked if TF-dependent proco-
agulant activity increased in activated cells. Freshly isolated 
platelets, at cell numbers (2 × 109 total) that approximate 
those found in 5–10 ml of whole blood, did not possess sig-
nifi  cant levels (P < 0.05) of procoagulant activity (Fig. 2, A 
and B). In contrast, procoagulant activity was markedly in-
creased as early as 5 min after platelets adhered to fi  brinogen 
in the presence of thrombin (Fig. 2 A) and continued to ac-
cumulate in platelets and platelet-derived microparticles in a 
time-dependent fashion (Fig. 2 B). Platelets activated in sus-
pension with ADP, collagen, or thrombin also accumulated 
TF-dependent procoagulant activity (unpublished data). We 
consistently observed that activated platelets possessed higher 
procoagulant activity than quiescent platelets in samples from 
diff  erent donors, but the magnitude was variable among sub-
jects, ranging from a 2.8- to a 15.3-fold increase over base-
line (mean increase over baseline 7.7 ± 2.0). In contrast to 
activated platelets, monocytes (5 × 106) stimulated with fi  b-
rinogen and thrombin did not generate appreciable proco-
agulant activity, although they did respond to lipopolysaccharide 
(unpublished data).
Next, we analyzed the protein by immunocytochemistry 
and observed TF on the surfaces of activated platelets that had 
adhered and spread on immobilized fi  brinogen in the pres-
ence of thrombin but not on quiescent platelets (Fig. 2 C). 
Figure 3.  Platelet Clk1 induces SF2/ASF phosphorylation. (A) Mega-
karyocytes with proplatelet extensions were stained with anti-Clk1 (top) 
or control IgG (bottom). The right panels are overlays where anti-Clk1 or 
IgG are in red, wheat germ agglutinin is in green, and topro-3, which 
stains nuclei, is in blue. (B) Platelets were left quiescent (top) or activated 
by adherence to immobilized fi  brinogen in the presence of thrombin for 
1 h (middle and bottom). The cells were stained with anti-Clk1 (top and 
middle) or control IgG (bottom). The right panels are overlays in which 
anti-Clk1 or IgG is in red, polymerized actin is in green, and colocalization 
of the two markers is identifi  ed by yellow staining. A and B are represen-
tative images of multiple cells taken from three and four independent 
experiments, respectively. (C and D) Platelets were activated as in B, lysed, 
and immune complex kinase assays for Clk1 activity were performed with 
recombinant SF2/ASF as the substrate. C shows a time course of Clk1-
dependent SF2/ASF phosphorylation in activated platelet lysates. D shows 
Clk1-dependent SF2/ASF phosphorylation in freshly isolated platelet 
lysates or platelets that were pretreated with vehicle or Tg003 (Clk Inh) 
(lanes 2–5). The bars for C and D represent fold increases in SF2/ASF 
phosphorylation over baseline as estimated by densitometry. The gels in 
C and D are representative of three independent experiments.JEM VOL. 203, October 30, 2006  2437
BRIEF DEFINITIVE REPORT
Staining was detected on the surface of all the platelets, consis-
tent with the detection of TF mRNA in every cell (Fig. 1 E, 
top right).
Deletion of factor VIIa from the activity assay or in-
cubation of platelets with a neutralizing anti-TF antibody 
signifi  cantly  (P  < 0.05) reduced procoagulant activity in 
stimulated platelets (Fig. 2, D and E). This activity assay, 
however, evaluates factor Xa generation in the presence of 
supraphysiologic levels of exogenous factor VIIa (7). There-
fore, we determined if platelet-derived TF decreased plasma 
clotting times. We found that human plasma incubated with 
platelets for 5 min or 2 h formed clots at an accelerated rate 
compared with freshly isolated platelets, which by them-
selves had no appreciable eff  ect on plasma clot formation 
(Fig. 2 F). Clotting was signifi  cantly delayed in the presence 
of an inhibitory anti-TF antibody (Fig. 2 F), indicating that 
TF generated by activated platelets is capable of accelerating 
in vitro clot formation in humans. Collectively, the studies 
depicted in Fig. 2 demonstrate that bioactive TF protein ac-
cumulates in platelets adherent to fi  brinogen in the presence 
of thrombin. The role of platelet-derived TF in the propa-
gation and stabilization of platelet clots in vitro and in vivo 
will require further studies using both human and murine 
thrombosis models.
Clk1 interfaces with the splicing machinery in platelets
The intracellular signaling pathways that control TF pre-
mRNA splicing and activity in platelets are not known (18). 
In nucleated cells, serine-arginine (SR)–rich proteins regu-
late splicing, and we recently found that human platelets 
contain the SR family member SF2/ASF (18). Thus, we consi-
dered that platelets possess critical upstream kinases that 
regulate SF2/ASF activity and focused on Clk family mem-
bers because one of them, Clk1, contains an N-  terminal 
Figure 4.  Interruption of Clk1 blocks signal-dependent TF pre-
mRNA splicing and bioactive protein accumulation in platelets. 
(A) Human TF pre-mRNA (pHTF; 904 bp) and mature mRNA (mHTF; 297 bp) 
was determined in freshly isolated platelets and in platelets adherent to 
immobilized fi  brinogen and coactivated with thrombin for 2 h. The acti-
vated platelets were either left untreated (lane 3) or pretreated with vehi-
cle (Veh) or Tg003 (Clk Inh). (B) Western blot analysis showing TF protein 
expression in platelets and platelet-derived microparticles. The platelets 
were left quiescent (baseline) or adhered to immobilized fi  brinogen and 
coactivated with thrombin for 30 min or 4 h in the presence or absence of 
Tg003 (Clk Inh). Recombinant TF was used as a positive control. The panels 
in A and B are representative of at least three independent experiments. 
(C) This panel depicts TF-dependent procoagulant activity in freshly iso-
lated platelets or platelets activated, as in Fig. 2 B, in the presence or ab-
sence of the Clk inhibitor. The data are displayed as pM of TF per 2 × 109 
platelets and represent the mean ± SEM of six independent experiments. 
A single asterisk (*) indicates a statistically signifi  cant difference (P < 
0.05) in TF-dependent procoagulant activity between freshly isolated 
(baseline) and activated platelets; the double asterisk (**) represents a 
signifi  cant difference (P < 0.05) between activated platelets under un-
treated or treated conditions. (D) These panels show plasma clot forma-
tion in the presence of membranes isolated from freshly isolated platelets 
(Control) or platelets activated for 5 min (left) or 2 h (right) with fi  brino-
gen and thrombin. The activated platelets were pretreated with either the 
Clk inhibitor (Clk Inh) or DMSO. The data represent the mean ± SEM of 
fi  ve independent experiments. The single asterisk (*) indicates a statisti-
cally signifi  cant difference (P < 0.05) in the rate of clot formation in 
plasma samples exposed to fi  brinogen and thrombin-treated platelets 
compared with quiescent platelets (Control) and activated platelets 
treated with the Clk inhibitor.2438  TISSUE FACTOR PRE-MRNA SPLICING IN PLATELETS | Schwertz et al.
region enriched in arginine-serine dipeptides (RS) that in-
teracts with SF2/ASF (21). We found Clk1 protein in the 
cytoplasm of mature megakaryocytes (unpublished data), 
in proplatelets that extend from the megakaryocytes (Fig. 
3 A, arrows), and in quiescent circulating platelets from 
human blood (Fig. 3 B, arrows). In activated platelets, Clk1 
was distributed to the tips of F-actin stress cables (Fig. 3 B). 
Intracellular redistribution of Clk1 resembles the accumu-
lation of vinculin in focal adhesion complexes of platelets 
that are spread and activated on immobilized fi  brinogen 
(unpublished data and reference 22). Preliminary screens for 
other family members (Clk2, 3, and 4) were negative (un-
published data), suggesting that Clk1 is the primary Clk in 
mature, circulating platelets.
In nucleated cells, Clk1 directly phosphorylates SF2/
ASF and alters the intracellular localization patterns of SR 
proteins (21). Therefore, we captured endogenous   platelet 
Clk1 by immunoprecipitation and determined if it regulates 
SF2/ASF phosphorylation. Clk1 from activated   platelets 
markedly increased SF2/ASF phosphorylation (Fig. 3 C). 
Increased SF2/ASF phosphorylation was not seen when control 
IgG was used as the immunoprecipitating reagent (Fig. 
S4 A, available at http://www.jem.org/cgi/content/full/
jem.20061302/DC1).
A benzothiazole compound, Tg003, suppresses Clk1-
catalyzed phosphorylation and thereby inhibits SF2/ASF-
  dependent splicing of in vitro–transcribed pre-mRNAs in 
immortalized cell lines (23). In stimulated platelets Tg003, 
but not its vehicle, suppressed Clk1-dependent SF2/ASF 
phosphorylation (Fig. 3 D), consistent with previous charac-
terization of the inhibitor in other cells (23).
Clk1 controls the expression of TF in activated platelets
We next asked if interruption of signaling from Clk1 to SF2/
ASF modulates activation-dependent splicing and found that 
Tg003 prevented processing of TF pre-mRNA in activated 
platelets (Fig. 4 A). This Clk1-dependent splicing inhibitor 
also blocked the expression of TF protein in activated platelets 
and platelet-derived microparticles (Fig. 4 B). Consistent with 
its eff  ect on protein, Tg003 signifi  cantly (P < 0.05) reduced 
TF-dependent procoagulant activity in stimulated platelets 
(Fig. 4 C) and delayed the onset of plasma clot formation 
(Fig. 4 D). Puromycin, an inhibitor of mRNA translation, 
also signifi  cantly (P < 0.05) reduced TF-dependent proco-
agulant activity demonstrating the increases were caused by 
de novo protein synthesis (Fig. S5, available at http://www.
jem.org/cgi/content/full/jem.20061302/DC1).
Although Tg003 blocked SF2/ASF phosphorylation (Fig. 
3 C) and the expression of TF protein in activated platelets 
(Fig. 4), it had no eff  ect on other platelet functional responses 
that included cellular adherence and spreading, actin polym-
erization, organization of β-tubulin, or the redistribution of 
Clk1 to focal adhesion complexes (Fig. S6, available at http://
www.jem.org/cgi/content/full/jem.20061302/DC1). These 
data suggest that the Clk1 signaling pathway primarily inter-
faces with the splicing machinery in platelets.
Conclusions
Pre-mRNA splicing and regulated translation of processed 
mRNAs are novel functions that allow activated platelets to 
alter their transcriptome and proteome in response to stimu-
lation (18, 20, 24). IL-1β was the fi  rst platelet product dis-
covered to be synthesized in this fashion (18). In this report, 
we demonstrate that platelets also use their splicing machin-
ery to control the expression of TF and identify a new in-
termediate, Clk1, in the signaling pathway leading to TF 
synthesis. Our results indicate that quiescent platelets contain 
TF pre-mRNA but do not express signifi  cant levels (P < 
0.05) of TF protein or activity under basal conditions. In 
contrast, activated platelets express both TF mRNA and bio-
active TF protein. Pre-mRNA splicing and translation of TF 
message into protein is observed as early as 5 min after activa-
tion and is sustained for at least 4 h. The time scale of this 
  response suggests that platelet-derived TF sustains the growth 
of the thrombus and increases its stability by enhancing fi  brin 
deposition (Fig. 5). Formation of a stable thrombus is essen-
tial for hemostasis and promotes wound healing at the site of 
vascular injury. Recent studies have found that mice with 
defi  ciencies in TF or fi  brinogen form unstable thrombi (25, 
26). Tissue factor also modulates infl  ammation and angio-
genesis (27, 28), indicating that it aff  ects prolonged functional 
responses. At present the relative contributions of platelet-
derived TF and TF-positive microparticles to thrombus for-
mation under diff  erent pathologic conditions are not known. 
Although on a per-cell basis lipopolysaccheride-stimulated 
monocytes generate greater amounts of TF than platelets 
(unpublished observations), the number of circulating plate-
lets far exceed (i.e.,  500–1,000-fold greater) the number of 
Figure 5.  Proposed model by which platelet-derived tissue factor 
contributes to propagation and stabilization of a thrombus.JEM VOL. 203, October 30, 2006  2439
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monocytes per volume of blood. In the case of platelets, our 
studies are the fi  rst to demonstrate that Clk1 modulates TF 
gene expression and suggest that splicing of TF pre-mRNA 
may be a potential therapeutic target in syndromes of disor-
dered coagulation.
MATERIALS AND METHODS
Cells. CD34+ stem cells were isolated from human umbilical cord blood 
and were diff  erentiated into megakaryocytes that produce proplatelets using 
methods that we have previously described (18). Leukocyte-depleted human 
platelets were isolated from healthy volunteers using previously described 
methods (18, 29). The human studies were approved by the University of 
Utah Internal Review Board (IRB approval numbers 392 and 11919).
mRNA detection systems. For most of the studies, primers that targeted 
sequences in exon four (5′-C  T  C  G  G  A  C  A  G  C  C  A  A  C  A  A  T  T  C  A  G  -3′) and 
fi  ve (5′-C  G  G  G  C  T  G  T  C  T  G  T  A  C  T  C  T  T  C  C  -3′), and thus spanned intron 
four, were used to determine endogenous splicing of TF pre-mRNA 
in platelets. Indirect in situ hybridization or direct in situ PCR was used 
to  detect TF pre-mRNA in megakaryocytes and platelets as previously 
  described (18).
Protein detection systems. Detailed strategies for protein detection by 
fl  ow cytometry, Western blot analysis, and immunocytochemistry have been 
previously published (18, 29).
Measurement of TF-dependent procoagulant activity. TF-dependent 
procoagulant activity was calculated with an Actichrome TF assay (American 
Diagnostica) as previously described (13).
Plasma clotting. Platelets were left quiescent or activated in the presence or 
absence of Tg003. Platelet membranes were isolated and added to human plasma 
(37°C), and clotting was initiated with CaCl2 as previously described (7).
Immune complex kinase assay for Clk1 activity. Clk1 activity in 
platelets was determined using an immune complex kinase assay. An an-
tibody against Clk1 was used for immunoprecipitation of the protein. 
Nonimmune rabbit IgG was used as a control, and in select experiments 
recombinant SF2/ASF was removed from the assays to screen for nonspe-
cifi  c incorporation of radiolabeled phosphate (Fig. S4, A and B). Kinase 
assays were performed by addition of recombinant SF2/ASF (Protein One) 
in the presence of γ-[32P]ATP (MP Biomedicals). At the end of this incuba-
tion period, the agarose beads and immune complexes were removed by 
centrifugation, and the unbound sample, which contained SF2/ASF, was 
resolved by SDS-PAGE.
Statistical analyses. ANOVA was conducted to identify diff  erences that 
existed among multiple experimental groups. If signifi  cant diff  erences were 
found, a Student-Newman-Keuls post-hoc procedure was used to deter-
mine the location of the diff  erence. For all of the analyses, P < 0.05 was 
considered statistically signifi  cant.
Online supplemental material. Supplemental Materials and methods de-
tails methods for cellular activation, in situ hybridization, and protein detec-
tion. Fig. S1 provides data from fl  ow cytometric analysis for CD45 or control 
IgG in leukocyte-depleted platelets or monocytes. Fig. S2 shows that acti-
vated platelets express full-length, mature (mHTF) human TF mRNA. Fig. 
S3 shows TF pre-mRNA splicing in human platelets due to activation with 
ADP, collagen, and thrombin in suspension. Fig. S4 provides additional data 
regarding the specifi  c Clk1-mediated SF2/ASF phosphorylation. Fig. S5 
shows that the inhibition of translation prevents activated platelets from gen-
erating bioactive tissue factor. Fig. S6 shows that inhibition of Clk1 does not 
adversely aff  ect platelet functional responses. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20061302/DC1.
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